| Document |
Document Title |
|
WO/2018/184985A1 |
Compounds of the formula (I): wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2018/184988A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2018/184185A1 |
Disclosed is an ozanimod addition salt crystal, which is provided with one or more improved characteristics compared with a known ozanimod solid form. Also disclosed are a preparation method for the ozanimod addition salt crystal, a phar...
|
|
WO/2018/184392A1 |
The present invention provides formula I and formula II IDO inhibitors and preparation methods therefor, wherein R1, R2, and X groups are as defined in the specification. The present invention also provides a pharmaceutical composition c...
|
|
WO/2018/184987A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2018/184984A1 |
Compounds of the formula (I): wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2018/184970A1 |
The present invention relates to novel trifluoromethyloxadiazoles of the formula (I), or the N-oxides, or the agriculturally useful salts thereof; and to their use for controlling phytopathogenic fungi; and to a method for combating phyt...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/187553A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, L and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Fo...
|
|
WO/2018/178304A1 |
Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.
|
|
WO/2018/183097A1 |
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disor...
|
|
WO/2018/177871A1 |
Disclosed are N-(1,3,4-oxadiazole-2-yl)aryl carboxamides of formula (I) or the salts (I) thereof as well as the use thereof as herbicides.
|
|
WO/2018/177880A1 |
A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of pl...
|
|
WO/2018/177894A1 |
A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of pl...
|
|
WO/2018/167468A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...
|
|
WO/2018/165520A1 |
Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
|
|
WO/2018/159841A1 |
The purpose of the present invention is to develop an optical resolution reagent for which quenching does not occur in the analysis of a chiral amino acid. The problem is solved by providing a novel compound for optical resolution that d...
|
|
WO/2018/153730A1 |
The present invention relates to novel trifluoromethyloxadiazoles of the formula I,or the N- oxides, or the agriculturally useful salts thereof; and to their use for controlling phytopathogenic fungi; and to a method for combating phytop...
|
|
WO/2018/156443A1 |
Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or dis...
|
|
WO/2018/140338A1 |
Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof, in which each of variables R1, R2, L, and Z is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-a...
|
|
WO/2018/137644A1 |
A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention a...
|
|
WO/2018/137128A1 |
A composition comprising an oxadiazole compound as represented by the following formula (I), used for preventing and/or treating ginger bacterial wilt, a method for preventing and/or treating ginger bacterial wilt using said compound, an...
|
|
WO/2018/133716A1 |
The present invention provides a heterocyclic urea compound as an indoleamine-2,3-dioxygenase inhibitor, a preparation method thereof, and a use of the heterocyclic urea compound as an indoleamine-2,3-dioxygenase inhibitor or a pharmaceu...
|
|
WO/2018/133870A1 |
A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.
|
|
WO/2018/129274A1 |
Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the structure (I) in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis...
|
|
WO/2018/119080A1 |
The present disclosure describes novel methods for treating a subject with a hepatic disorder. Specifically, the methods include the administration of an S1P1-selective agent to a subject in order to stimulate liver tissue development, v...
|
|
WO/2018/114393A1 |
The present invention relates to novel trifluoromethyloxadiazoles of the formula (I) or an N-oxide and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, or to a method for combating phytopathoge...
|
|
WO/2018/117034A1 |
Provided are a plant disease control method, said method comprising applying a compound represented by formula (I) to a plant or soil, and the compound. [In formula (I): G represents a thiophene ring, a furan ring, etc.; n represents 1, ...
|
|
WO/2018/113758A1 |
Provided in the present application are a sulfonyl amidine as represented by formula (I) as an indoleamine-2,3-dioxygenase inhibitor, and a preparation method therefor and the use thereof. The compound of formula (I) in the present appli...
|
|
WO/2018/110669A1 |
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and meth...
|
|
WO/2018/095432A1 |
Provided are certain IDO inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2018/093762A1 |
Furoxan compounds, compositions comprising the same, and methods of making and using the same, are described.
|
|
WO/2018/083241A1 |
The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enant...
|
|
WO/2018/081167A1 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2018/080859A1 |
Disclosed are compounds of Formula I, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, Z1, R2, Z2, J, s and f are as defined in the disclosure. Also disclosed are compositions containing the ...
|
|
WO/2018/081425A1 |
Described herein are compounds having a hydrogen-bonding group and optionally a functional group for binding (e.g., covalently binding) the compound to another compound (e.g., hyaluronic acid and/or gelatin). A compound of the present in...
|
|
WO/2018/073754A1 |
The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as V-domain immunoglobulin suppressor of T-cell activation (VISTA) inhibitors or as dual inhibitors of VISTA and the progr...
|
|
WO/2018/072697A1 |
Disclosed are an oxadiazole ring-containing compound, a preparation method therefor, and an intermediate, a composite, and an application thereof. The oxadiazole ring-containing compound having the formula in the figure below, and a phar...
|
|
WO/2018/065414A1 |
Compounds of Formula (I): wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2018/062978A1 |
The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds repr...
|
|
WO/2018/055135A1 |
A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally effective amount of a compound of Formula (I) wherein the substituents are as defined in claim 1, is applied to ...
|
|
WO/2018/056340A1 |
The present invention provides a compound having excellent control efficacies against plant diseases. Specifically, the present invention provides a compound represented by formula (1) (wherein: X represents a C3-C5 alkyl group or a NR1R...
|
|
WO/2018/051254A1 |
The present invention relates to cyclic substituted-1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signalling pathway and/or for treatment of disorders by inhibiting an immunosuppress...
|
|
WO/2018/049632A1 |
The invention relates to a crystal form of ozanimod. Compared with known forms of ozanimod, the crystal form of ozanimod of the invention has one or more improved features. The invention also relates to a preparation method and a pharmac...
|
|
WO/2018/049404A1 |
Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins tha...
|
|
WO/2018/047139A1 |
The present invention relates to compound of formula (I) as therapeutic agents to modulate the TIGIT signalling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceuticall...
|
|
WO/2018/044663A1 |
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated dis...
|
|
WO/2018/039430A1 |
Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [18F]IDO49 specifically accumulate in IDO-expres...
|
|
WO/2018/033149A1 |
Provided are crystal forms of Ozanimod and a preparation method therefor. The provided crystal forms of Ozanimod comprise a crystal form CS9, a crystal form CS10, and a crystal form CS11 of Ozanimod, and can be used for treating autoimmu...
|
|
WO/2018/030460A1 |
The present invention provides a compound having excellent control efficacies against pests. Specifically, the present invention provides a compound represented by formula (I):(wherein: G represents a benzene ring or pyridine ring, etc.;...
|
